PolyPid Announces Participation in Upcoming Investor Conferences
PETACH TIKVA, Israel,
Citizens 2026
- Date:
March 10, 2026 at1:40 pm ET - Location: Eden Roc Miami Beach,
Miami Beach, FL - Format: Fireside chat
- Webcast Signup: https://event.summitcast.com/view/BuMiPNPtyHKimMF6k4AFMd/bygPbooQTs4VTXiUdoDYrb
Investors who wish to meet with
38th Annual
- Date:
March 23, 2026 , at12:30 PM PT - Location: The
Ritz-Carlton, Laguna Niguel ,Dana Point, CA - Format: Fireside chat
Investors who wish to meet with
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.
Company Contact:
908-858-5995
IR@Polypid.com
Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com
Source: PolyPid Ltd.